Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG, and what generic alternatives to SHANDONG drugs are available?
SHANDONG has twelve approved drugs.
There are five US patents protecting SHANDONG drugs. There is one tentative approval on SHANDONG drugs.
There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and thirty-four supplementary protection certificates in eleven countries.
Summary for Shandong
| International Patents: | 29 |
| US Patents: | 5 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 12 |
Drugs and US Patents for Shandong
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong | ISOSORBIDE MONONITRATE | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 214115-003 | Feb 8, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 202413-004 | Jul 5, 2024 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 207095-002 | Aug 21, 2018 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Shandong | ISOSORBIDE MONONITRATE | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 214115-002 | Feb 8, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
Supplementary Protection Certificates for Shandong Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1003503 | 30/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707 |
| 1003503 | C01003503/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006 |
| 0287150 | 96C0038 | Belgium | ⤷ Sign Up | PRODUCT NAME: ROCURONIUMBROMIDE; NAT. REGISTRATION NO/DATE: 63 IS 9 F 12 19960709; FIRST REGISTRATION: NL RVG 16946 19940406 |
| 1003503 | 05C0048 | France | ⤷ Sign Up | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
